candesartan has been researched along with Autoimmune Diabetes in 23 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report the experience from DIRECT (DIabetic REtinopathy and Candesartan Trials), three placebo-controlled studies designed to examine the effects of an ARB, candesartan, on diabetic retinopathy." | 9.15 | Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials. ( Bilous, R; Chaturvedi, N; Fuller, JH; Hainer, JW; Jansson, SO; Klein, R; Malm, A; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2011) |
| "To determine whether the angiotensin-receptor blocker candesartan compared with placebo affects microalbuminuria incidence or rate of change in albuminuria in type 1 and type 2 diabetes." | 9.14 | Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. ( Bilous, R; Chaturvedi, N; Fuller, J; Klein, R; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2009) |
| " We report the experience from DIRECT (DIabetic REtinopathy and Candesartan Trials), three placebo-controlled studies designed to examine the effects of an ARB, candesartan, on diabetic retinopathy." | 5.15 | Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials. ( Bilous, R; Chaturvedi, N; Fuller, JH; Hainer, JW; Jansson, SO; Klein, R; Malm, A; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2011) |
| "To study the association between baseline retinal microaneurysm score and progression and regression of diabetic retinopathy, and response to treatment with candesartan in people with diabetes." | 5.15 | Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme. ( Aldington, S; Bilous, R; Chaturvedi, N; Fuller, J; Klein, R; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2011) |
| "To determine whether the angiotensin-receptor blocker candesartan compared with placebo affects microalbuminuria incidence or rate of change in albuminuria in type 1 and type 2 diabetes." | 5.14 | Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. ( Bilous, R; Chaturvedi, N; Fuller, J; Klein, R; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2009) |
| "To assess and compare the long-term effects of the combination of candesartan and lisinopril with high-dose lisinopril on systolic blood pressure in patients with hypertension and diabetes." | 5.11 | Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. ( Andersen, NH; Eiskjaer, H; Hansen, KW; Helleberg, K; Knudsen, ST; Mogensen, CE; Poulsen, PL; Poulsen, SH, 2005) |
| "There was a wide range of changes in RPF and GFR in response to the two agents, each administered at the top of its dose-response range." | 2.71 | Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. ( Fisher, ND; Gordon, MS; Hollenberg, NK; Laffel, LM; Lansang, MC; Perkins, B; Price, DA; Williams, GH, 2003) |
| "Twenty-eight patients who had type 1 diabetes and known diabetic renal disease and had a persistently elevated albumin creatinine ratio (ACR) > 10 mg/mmol despite office BP recordings < or = 140/80 mmHg on maximal recommended dose of the ACEI lisinopril were studied." | 2.71 | Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease. ( Bilous, R; Karalliedde, J; Krimholtz, MJ; Thomas, S; Viberti, G, 2005) |
| "Type 1 diabetes was induced in rats by intraperitoneally injecting spontaneously hypertensive rats with streptozotocin." | 1.35 | Candesartan and insulin reduce renal sympathetic nerve activity in hypertensive type 1 diabetic rats. ( Hayashi, K; Iigaya, K; Itoh, H; Kamayachi, T; Kumagai, H; Onami, T; Osaka, M; Sakata, K; Saruta, T; Takimoto, C, 2008) |
| "We report here a case of type I diabetes mellitus with secondary FGS accompanied by proteinuria 10 months following kidney transplantation." | 1.33 | Secondary focal segmental glomerulosclerosis following kidney transplantation in a patient with type I diabetes mellitus. ( Hosoya, T; Mitome, J; Miyazaki, Y; Tanno, Y; Utsunomiya, Y; Yamaguchi, Y; Yamamoto, H; Yamamoto, I, 2006) |
| "Twelve patients with type 1 diabetes mellitus of 18 +/- 3." | 1.31 | Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus. ( Erani, D; Fisher, ND; Hollenberg, NK; Laffel, LM; Lansang, MC; Osei, SY; Price, DA, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (65.22) | 29.6817 |
| 2010's | 8 (34.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdul-Rahim, AH | 1 |
| Perez, AC | 1 |
| Fulton, RL | 1 |
| Jhund, PS | 1 |
| Latini, R | 1 |
| Tognoni, G | 1 |
| Wikstrand, J | 1 |
| Kjekshus, J | 1 |
| Lip, GY | 1 |
| Maggioni, AP | 1 |
| Tavazzi, L | 1 |
| Lees, KR | 1 |
| McMurray, JJ | 1 |
| Mitchell, P | 1 |
| Wong, TY | 1 |
| Chaturvedi, N | 6 |
| Porta, M | 6 |
| Klein, R | 6 |
| Orchard, T | 4 |
| Fuller, J | 3 |
| Parving, HH | 5 |
| Bilous, R | 6 |
| Sjølie, AK | 8 |
| Takimoto, C | 1 |
| Kumagai, H | 1 |
| Osaka, M | 1 |
| Sakata, K | 1 |
| Onami, T | 1 |
| Kamayachi, T | 1 |
| Iigaya, K | 1 |
| Hayashi, K | 1 |
| Saruta, T | 1 |
| Itoh, H | 1 |
| Wright, AD | 1 |
| Dodson, PM | 1 |
| Naviglio, S | 1 |
| Pirozzi, F | 1 |
| Moss, SE | 1 |
| Malm, AR | 1 |
| Fuller, JH | 2 |
| Hainer, JW | 1 |
| Jansson, SO | 1 |
| Malm, A | 1 |
| Dodson, P | 1 |
| Hobbs, FR | 1 |
| Aldington, S | 1 |
| Schlaich, MP | 1 |
| Hollenberg, NK | 5 |
| Price, DA | 5 |
| Fisher, ND | 4 |
| Lansang, MC | 5 |
| Perkins, B | 1 |
| Gordon, MS | 1 |
| Williams, GH | 2 |
| Laffel, LM | 5 |
| Stevanovic, R | 2 |
| Agarwal, A | 1 |
| Andersen, NH | 1 |
| Poulsen, PL | 1 |
| Knudsen, ST | 1 |
| Poulsen, SH | 1 |
| Eiskjaer, H | 1 |
| Hansen, KW | 1 |
| Helleberg, K | 1 |
| Mogensen, CE | 1 |
| Krimholtz, MJ | 1 |
| Karalliedde, J | 1 |
| Thomas, S | 1 |
| Viberti, G | 1 |
| Stevanovic, RD | 1 |
| Yamamoto, I | 1 |
| Yamamoto, H | 1 |
| Mitome, J | 1 |
| Tanno, Y | 1 |
| Utsunomiya, Y | 1 |
| Miyazaki, Y | 1 |
| Yamaguchi, Y | 1 |
| Hosoya, T | 1 |
| Perrin, NE | 1 |
| Jaremko, GA | 1 |
| Berg, UB | 1 |
| Osei, SY | 1 |
| Erani, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial[NCT04696120] | Phase 2 | 200 participants (Anticipated) | Interventional | 2021-03-02 | Not yet recruiting | ||
| Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients Without Retinopathy.[NCT00252733] | Phase 3 | 5,238 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| DIRECT: DIabetic Retinopathy Candesartan Trials. Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients With Retinopathy.[NCT00252720] | Phase 3 | 1,850 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 2 Diabetic Patients With Retinopathy.[NCT00252694] | Phase 3 | 4,717 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Prospective, Single-center, Six-month Study of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy: Effects on Microaneurysm Turnover and Non-perfused Retinal Area[NCT02834663] | Phase 4 | 25 participants (Actual) | Interventional | 2016-08-31 | Completed | ||
| Studies of Early Diabetic Glomerulopathy-the Relation Between Histopathology, Kidney Function and Metabolic Control. Natural History and Effect of ARB[NCT00328302] | Phase 4 | 13 participants | Interventional | 2000-09-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Two steps were defined as either a 1-step change in each eye or as a 2-step change in one eye only. ETDRS is a scale with 11 steps (1-11, where a score of 1 represents no retinopathy and a score of 11 represents proliferative retinopathy). A generalized log-rank test was used to test difference between treatments. (NCT00252733)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 178 |
| Placebo | 217 |
An estimate of the slope from fitting a linear regression of log(UAER) over time for each patient. (NCT00252733)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/year (Least Squares Mean) |
|---|---|
| Candesartan | 0.510 |
| Placebo | 0.543 |
Retinopathy progression was defined as the first occurrence of at least a 3-step increase in the ETDRS severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments. (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 127 |
| Placebo | 124 |
Regression of diabetic retinopathy was defined as at least a 3 step improvement or a persistent 2-step improvement (confirmed in 2 consecutive photography sets) in the Early Treatment of Diabetic Retinopathy Study (ETDRS) severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). (NCT00252720)
Timeframe: From baseline to the end of the study, i.e., 5 years
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 140 |
| Placebo | 139 |
Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs. (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 110 |
| Placebo | 107 |
An estimate of the slope from fitting a linear regression of log (UAER) over time (post-randimisation, yearly assessments) for each patient (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/year (Least Squares Mean) |
|---|---|
| Candesartan | 0.569 |
| Placebo | 0.642 |
3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments. (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 161 |
| Placebo | 182 |
3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 180 |
| Placebo | 136 |
Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs. (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 192 |
| Placebo | 193 |
An estimate of the slope from fitting a linear regression of log(UAER) over time (post-randomisation, yearly assessments) for each patient. (NCT00252694)
Timeframe: From Baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/1000 year (Least Squares Mean) |
|---|---|
| Candesartan | 656 |
| Placebo | 718 |
CRT was performed using OCT at each visit. The OCT measured at each visit was analyzed statistically. the CMT compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months
| Intervention | um (Mean) |
|---|---|
| CRT Baseline | 479.12 |
| CRT Resulte | 369.12 |
Using ImageJ software (version 1.52a) by FAG image. The Perifoveal non-perfusion area in FAG compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months
| Intervention | mm2 (Mean) |
|---|---|
| Perifoveal Non-perfusion Area Baseline | 2.517 |
| Perifoveal Non-perfusion Area Results | 2.495 |
Systemic adverse events (MI, CVA, etc), Ocular adverse events (retinal detachment, RPE tear, endophthalmitis, uveitis, vitreous hemorrhage, subretinal hemorrhage, cataract , IOP elevation, etc) at baseline and each visit. (NCT02834663)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Safety Parameters Results | 0 |
BCVA was performed using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at baseline and 6 months. The BCVA compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months
| Intervention | letters (Mean) |
|---|---|
| BCVA Baseline | 67.6 |
| BCVA Resulte | 76.36 |
Number of MAs that resolved/month The MAs in individual retinas were evaluated at 6 months using fundus photography. The Retmarker (version 1.0.2 by Retmarker Ltd, Coimbra, Portugal) software was used for automatic measurement and analysis of changes in number and extent of MAs on fundus photographs and to calculate the total number and turnover of MAs. MA turnover was calculated by adding the MA formation rate (number of new MAs detected/month) to the MA disappearance rate (number of MAs that resolved/month). The microaneurysm disappearance rate compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months
| Intervention | microaneurysms/month (Mean) |
|---|---|
| The MA Disappearance Rate Baseline | 4.40 |
| The MA Disappearance Rate Resulte | 0.96 |
number of new MAs detected/month The MAs in individual retinas were evaluated at 6 months using fundus photography. The Retmarker (version 1.0.2 by Retmarker Ltd, Coimbra, Portugal) software was used for automatic measurement and analysis of changes in number and extent of MAs on fundus photographs and to calculate the total number and turnover of MAs. MA turnover was calculated by adding the MA formation rate (number of new MAs detected/month) to the MA disappearance rate (number of MAs that resolved/month). The microaneurysm formation rate compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months
| Intervention | microaneurysms/month (Mean) |
|---|---|
| The MA Formation Rate Baseline | 2.48 |
| The MA Formation Rate Resulte | 0.96 |
The microaneurysm formation rate + The microaneurysm disappearance rate The MAs in individual retinas were evaluated at 6 months using fundus photography. The Retmarker (version 1.0.2 by Retmarker Ltd, Coimbra, Portugal) software was used for automatic measurement and analysis of changes in number and extent of MAs on fundus photographs and to calculate the total number and turnover of MAs. MA turnover was calculated by adding the MA formation rate (number of new MAs detected/month) to the MA disappearance rate (number of MAs that resolved/month). The microaneurysm turnover compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months
| Intervention | microaneurysms/month (Mean) |
|---|---|
| The Microaneurysm Turnover Baseline | 6.88 |
| The Microaneurysm Turnover Results | 1.92 |
The number of MAs in individual retinas were evaluated during 6 months using fundus photography and FA imaging. The Retmarker software was used for automatic measurement and analysis of changes in number and extent of MAs on fundus photographs and to calculate the total number and turnover of MAs. Changes in MAs were analyzed statistically. the total number of MAs compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months
| Intervention | microaneurysms (Mean) |
|---|---|
| Total MA Baseline | 5.68 |
| Total MA Resulte | 1.60 |
4 reviews available for candesartan and Autoimmune Diabetes
| Article | Year |
|---|---|
Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; Biomarkers; Biphenyl Compounds; | 2015 |
Diabetic retinopathy and blockade of the renin-angiotensin system: new data from the DIRECT study programme.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2010 |
Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2011 |
The retinal renin-angiotensin system: implications for therapy in diabetic retinopathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biphenyl Compound | 2002 |
11 trials available for candesartan and Autoimmune Diabetes
| Article | Year |
|---|---|
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diab | 2008 |
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diab | 2008 |
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diab | 2008 |
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diab | 2008 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2009 |
Angiotensin receptor blockade not related to history of dry eye symptoms and treatment in The Diabetic Retinopathy Candesartan Trials (DIRECT).
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitu | 2011 |
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Bi | 2011 |
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Bi | 2011 |
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Bi | 2011 |
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Bi | 2011 |
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Bi | 2011 |
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Bi | 2011 |
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Bi | 2011 |
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Bi | 2011 |
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Bi | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus.
Topics: Adolescent; Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles | 2003 |
Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus | 2005 |
Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease.
Topics: Adult; Aged; Albuminuria; Amlodipine; Benzimidazoles; Biphenyl Compounds; Cross-Over Studies; Diabet | 2005 |
The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type | 2005 |
Renin release in response to Renin system blockade: activation of the Renin system in type 1 diabetes mellitus.
Topics: Adult; Aged; Aging; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Ca | 2005 |
The effects of candesartan on diabetes glomerulopathy: a double-blind, placebo-controlled trial.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biopsy; Biphenyl Compounds; Blood Pr | 2008 |
8 other studies available for candesartan and Autoimmune Diabetes
| Article | Year |
|---|---|
DIRECT new treatments for diabetic retinopathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabete | 2008 |
Candesartan and insulin reduce renal sympathetic nerve activity in hypertensive type 1 diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; | 2008 |
Renin-Angiotensin system blockade for diabetic nephropathy prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Typ | 2010 |
Angiotensin receptor blockade in diabetic women of childbearing potential: an acceptable risk?
Topics: Abnormalities, Drug-Induced; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; D | 2011 |
Plasma aldosterone concentration in the patient with diabetes mellitus.
Topics: Adolescent; Adult; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Benzimidazo | 2004 |
ACE and non-ACE pathways in the renal vascular response to RAS interruption in type 1 diabetes mellitus.
Topics: Adult; Benzimidazoles; Biphenyl Compounds; Captopril; Diabetes Mellitus, Type 1; Female; Glomerular | 2005 |
Secondary focal segmental glomerulosclerosis following kidney transplantation in a patient with type I diabetes mellitus.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidaz | 2006 |
Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biphenyl C | 2001 |